Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs

British Journal of Pharmacology

Volumn 158, Issue 6, 2009, Pages 1536-1547

  Choppin, A ^a   Irwin, I ^a   Lach, L ^a   McDonald, M G ^b   Rettie, A E ^b   Shao, L ^a   Becker, C ^a   Palme, M P ^a   Paliard, X ^a   Bowersox, S ^a   Dennis, D M ^a   Druzgala, P ^a  

^a ARYx Therapeutics   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Amiodarone; Beagle dogs; Coagulation factors; Tecarfarin; Warfarin

Indexed keywords

AMIODARONE; ANTIVITAMIN K; ATI 5900; ATI 5923; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; CYTOCHROME P450 2C9; DRUG METABOLITE; FRESH FROZEN PLASMA; OXIDOREDUCTASE; PHYTOMENADIONE; TECARFARIN; THROMBOPLASTIN; UNCLASSIFIED DRUG; VITAMIN K1 EPOXIDE REDUCTASE; WARFARIN;

ANIMAL EXPERIMENT; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING TIME; CONTINUOUS INFUSION; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; EXPERIMENTAL DOG; FEMALE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOPLASTIN TIME; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; AMIODARONE; ANIMALS; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BENZOATES; COUMARINS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FACTOR VII; FACTOR X; FEMALE; INFUSIONS, INTRAVENOUS; MALE; MIXED FUNCTION OXYGENASES; PROTHROMBIN TIME; WARFARIN;

EID: 70350538720     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00420.x     Document Type: Article

References (19)

1. Almog S, Shafran N, Halkin H, Weiss P, Farfel Z, Martinowitz U et al. (1985). Mechanism of warfarin potentiation by amiodarone: dose-and concentration-dependent inhibition of warfarin elimination. Eur J Clin Pharmacol 28 : 257 261.
2. Crowther MA, Julian J, McCarty D, Douketis J, Kovacs M, Biagoni L et al. (2000). Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet 356 : 1551 1553.
3. DiaPharma (2004). Factor X assay receives FDA approval for monitoring anticoagulation. Available at: http://www.diapharma.com/company/news-archive/ diapharma-factor-x-kit-cleared (accessed 2009).
4. Dowd P, Ham SW, Marchand AP, Rajapasksa D (1992). Mechanism of epoxidation of vitamin K with basic hydrogen peroxide. J Org Chem 57 : 3514 3516.
5. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM et al. (2002). Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287 : 1690 1698.
6. Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Deykin D (2001). Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119 : 8S 21S.
7. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M et al. (2005). Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165 : 1095 1106.
8. Irwin I, Davies A, Shao L, Kumaraswamy P, Lightning L, Choppin A et al. (2006). Pharmacokinetics and pharmacodynamics of ATI-5923, a novel VKOR inhibitor, in the dog. Drug Metab Rev 38 : 93.
9. Lindh JD, Lundgren S, Holm L, Alfredsson L, Rane A (2005). Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin Pharmacol Ther 78 : 540 550.
10. Medical Directors Advisory Committee, National Blood Transfusion Council (1998). Guideline for the use of fresh-frozen plasma. S Afr Med J 88 : 1344 1347.
11. Monnet E, Morgan M (2000). Effect of three loading doses of warfarin on the international normalized ratio for dogs. Am J Vet Res 61 : 48 50.
12. Odén A, Fahlén M (2002). Oral anticoagulation and risk of death: a medical record linkage study. BMJ 325 : 1073 1075.
13. Quick AJ (1935). The prothrombin time in hemophilia and in obstructive jaundice. J Biol Chem 109 : 73 74.
14. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL et al. (2005). Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352 : 2285 2293.
15. Riegert-Johnson DL, Volcheck GW (2002). The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review. Ann Allergy Asthma Immunol 89 : 400 406.
16. Serlin MJ, Breckenridge AM (1983). Drug interactions with warfarin. Drugs 25 : 610 620.
17. Usman MH, Notaro LA, Patel H, Ezekowitz MD (2008). New developments in anticoagulation for atrial fibrillation. Curr Treat Options Cardiovasc Med 10 : 388 397.
18. Veenstra DL, Blough DK, Higashi MK, Farin FM, Srinouanprachan S, Rieder MJ et al. (2005). CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin Pharmacol Ther 77 : 353 364.
19. Yiu KH, Siu CW, Jim MH, Tse HF, Fan K, Chau MC et al. (2006). Comparison of the efficacy and safety profiles of intravenous vitamin K and fresh frozen plasma as treatment of warfarin-related over-anticoagulation in patients with mechanical heart valves. Am J Cardiol 97 : 409 411.